<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796821</url>
  </required_header>
  <id_info>
    <org_study_id>GESRTGWA</org_study_id>
    <nct_id>NCT01796821</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)</brief_title>
  <official_title>A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G&amp;E Herbal Biotechnology Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G&amp;E Herbal Biotechnology Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of SR-T100 gel by observing total clearance rate of treated baseline&#xD;
      EGW(s) on the treated area.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized,vehicle-controlled, parallel-group, and dose-ranging study to&#xD;
      evaluate the efficacy and safety of SR-T100 gel in patients with EGW(s). The primary efficacy&#xD;
      endpoint will be defined as the proportion of patients whose baseline EGW(s) on the treated&#xD;
      area achieve total clearance. The efficacy of SR-T100 gel in prevention of new EGW(s)&#xD;
      occurrence will be evaluated. Distinct to existing medications for EGWs, SR-T100 gel&#xD;
      possesses characteristics of high safety and low LSR causality. SR-T100 gel will be&#xD;
      administered on EGW lesion(s) for clearance and on the surrounding clinical normal skin for&#xD;
      prevention of new EGW(s) occurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total clearance rate of baseline lesion(s)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total clearance rate of all lesion(s)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period duration of achieving total clearance of baseline lesion(s) and new lesion(s)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial clearance rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New lesion(s) occurrence rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate in the 12-week follow-up time</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence time period</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: evaluate the changes occurring from baseline to EOT visit</measure>
    <time_frame>28 weeks</time_frame>
    <description>including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Condyloma Acuminata</condition>
  <condition>Genital Warts</condition>
  <condition>Condylomata Acuminata</condition>
  <condition>Venereal Warts</condition>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SR-T100 gel with 1.0 % SM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SR-T100 gel with 2.3% SM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.&#xD;
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.&#xD;
Total application &lt;1,500 mg gel per day.</description>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-T100 gel with 1.0 % SM</intervention_name>
    <description>Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.&#xD;
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.&#xD;
Total application &lt;1,500 mg gel per day.</description>
    <arm_group_label>SR-T100 gel with 1.0 % SM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-T100 gel with 2.3% SM</intervention_name>
    <description>Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.&#xD;
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.&#xD;
Total application &lt;1,500 mg gel per day.</description>
    <arm_group_label>SR-T100 gel with 2.3% SM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female; aged ≥ 20 years old.&#xD;
&#xD;
          2. Patients who accept to enter the study by signing written informed consent.&#xD;
&#xD;
          3. Each patient has 1 to 10 clinically diagnosed EGW(s). If patient has only 1 genital&#xD;
             wart, the diameter of the genital wart must be no less than 5 mm.&#xD;
&#xD;
          4. Female patients have lesion(s) on labia majora, labia minora, clitoris and/or groin.&#xD;
&#xD;
          5. Male patients have lesion(s) on glans, shaft and/or foreskin.&#xD;
&#xD;
          6. Each patient has at least 1 histologically proved EGW.&#xD;
&#xD;
          7. Patients agree to apply the study medication on &quot;clinical diagnosed lesion(s)&quot; with&#xD;
             occlusive dressing(s) once daily for at least 20 hours per day and &quot;clinical normal&#xD;
             skin on the treated area&quot; thrice daily without occlusive dressing.&#xD;
&#xD;
          8. Patients allow diagrammed mapping and photography on genital warts. And patients agree&#xD;
             to be used of these data as part of the study data package.&#xD;
&#xD;
          9. Patients in good general health condition (performance status ≤ 2 Eastern Cooperative&#xD;
             Oncology Group (ECOG)).&#xD;
&#xD;
         10. Female patients with child-bearing potential must take reliable contraception&#xD;
             method(s) during the participation of the study.&#xD;
&#xD;
         11. Patients must agree to use effective boundary barrier for birth control and&#xD;
             re-infection of EGW&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with peri-anal warts.&#xD;
&#xD;
          2. Male patients with warts on scrotum or perineum.&#xD;
&#xD;
          3. Patients with other genital infections.&#xD;
&#xD;
          4. Patients with internal genital warts (such as urethral, intra-vaginal, cervical,&#xD;
             rectal, or intra-anal genital warts).&#xD;
&#xD;
          5. Patients with active systemic infections.&#xD;
&#xD;
          6. Patients with other genital diseases that may confound evaluation and treatment for&#xD;
             genital warts.&#xD;
&#xD;
          7. Patients with immuno-compromised medical condition.&#xD;
&#xD;
          8. Patients have received investigational drug prior to 30 days of randomization visit.&#xD;
&#xD;
          9. Patients with cancer or cancer history within 5 years of the randomization visit.&#xD;
&#xD;
         10. Patients have on-going human papilloma virus (HPV) infection other than genital area.&#xD;
&#xD;
         11. Patients with human immunodeficiency virus (HIV), venereal disease research laboratory&#xD;
             (VDRL), or treponema pallidum particle agglutination assay (TPHA) positive result.&#xD;
&#xD;
         12. Female patients have high-grade pathology in Papanicolaou smear tests based on&#xD;
             Bethesda system.&#xD;
&#xD;
         13. Female patients are pregnant or lactating.&#xD;
&#xD;
         14. Patients have history of allergy or sensitivity to Solanum undatum plant extract, SM,&#xD;
             or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.&#xD;
&#xD;
         15. Patients with prohibited pre-medication or procedures shown below:&#xD;
&#xD;
               1. Physical modalities, such as laser ablation, electrocautery or cryotherapy, for&#xD;
                  genital warts treatment on treated area within 4 weeks prior to randomization&#xD;
                  visit.&#xD;
&#xD;
               2. Topical administered medication for genital warts treatment, such as polyphenon&#xD;
                  E, podophyllotoxin, imiquimod, or 5-fluorouracil (5-FU), within 12 weeks prior to&#xD;
                  randomization.&#xD;
&#xD;
               3. Medications of cytotoxic, immunomodulator (inhaled and topical steroid not on&#xD;
                  ano-genital areas are not prohibited), systematic antiviral agent in 4 weeks&#xD;
                  prior to randomization visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kou-Wha Kuo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>G&amp;E Herbal Biotechnology Co., LTD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Yang Chou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng Kung University, Tainan, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Municipal Ta-Tung Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Condyloma acuminata</keyword>
  <keyword>Genital warts</keyword>
  <keyword>Condylomata acuminata</keyword>
  <keyword>Venereal warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

